Research ExplorerPublicationsCan a pathological complete response of breast cancer after ...

Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?

Standard

Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? / Heil, Joerg; Schaefgen, Benedikt; Sinn, Peter; Richter, Hannah; Harcos, Aba; Gomez, Christina; Stieber, Anne; Hennigs, André; Rauch, Geraldine; Schuetz, Florian; Sohn, Christof; Schneeweiss, Andreas; Golatta, Michael.

In: EUR J CANCER, Vol. 69, 12.2016, p. 142-150.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heil, J, Schaefgen, B, Sinn, P, Richter, H, Harcos, A, Gomez, C, Stieber, A, Hennigs, A, Rauch, G, Schuetz, F, Sohn, C, Schneeweiss, A & Golatta, M 2016, 'Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?', EUR J CANCER, vol. 69, pp. 142-150. https://doi.org/10.1016/j.ejca.2016.09.034

APA

Heil, J., Schaefgen, B., Sinn, P., Richter, H., Harcos, A., Gomez, C., Stieber, A., Hennigs, A., Rauch, G., Schuetz, F., Sohn, C., Schneeweiss, A., & Golatta, M. (2016). Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? EUR J CANCER, 69, 142-150. https://doi.org/10.1016/j.ejca.2016.09.034

Vancouver

Heil J, Schaefgen B, Sinn P, Richter H, Harcos A, Gomez C et al. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? EUR J CANCER. 2016 Dec;69:142-150. https://doi.org/10.1016/j.ejca.2016.09.034

Bibtex

@article{198017518eea4835b5ccf2fdddd6d3bc,
title = "Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?",
abstract = "BACKGROUND: This study aimed to explore the ability of a minimal invasive biopsy to diagnose a pathological complete response (pCR = ypT0) in the breast.METHODS: Ultrasound-guided, vacuum-assisted, minimal invasive biopsy (VAB) was performed in 50 patients after neoadjuvant chemotherapy and before breast surgery. Negative predictive values (NPV) and false negative rates (FNR) to predict a pCR in surgical specimen were the main outcome measures. To assess the possible sampling error, the representativeness of the sample was evaluated by the biopsy performing physician (subjectively based on the visibility in ultrasound), by radiography of the biopsy specimen, and by the pathologist (based on histopathology).RESULTS: The cohort (n = 50) consisted of 15 (30%) triple negative breast cancers, 13 (26%) human epidermal growth factor receptor 2 (HER2) positive and 22 (44%) hormone receptor positive/HER2 negative cancers. ypT0 was diagnosed in 23 (46%) cases. In the overall cohort (n = 50), VAB yielded an NPV of 76.7% and an FNR of 25.9%. Given a representative VAB sample, according to the histopathological evaluation (n = 38), the NPV was 94.4% (95% CI 87.1-100.0) and the FNR 4.8% (95% CI 0.0-11.6). Non-representative VABs were mainly due to bad visibility of the target lesion in ultrasound.CONCLUSION: A VAB can accurately diagnose a pCR, given a histopathologically representative sample.",
author = "Joerg Heil and Benedikt Schaefgen and Peter Sinn and Hannah Richter and Aba Harcos and Christina Gomez and Anne Stieber and Andr{\'e} Hennigs and Geraldine Rauch and Florian Schuetz and Christof Sohn and Andreas Schneeweiss and Michael Golatta",
note = "Copyright {\^A}{\textcopyright} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = dec,
doi = "10.1016/j.ejca.2016.09.034",
language = "English",
volume = "69",
pages = "142--150",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?

AU - Heil, Joerg

AU - Schaefgen, Benedikt

AU - Sinn, Peter

AU - Richter, Hannah

AU - Harcos, Aba

AU - Gomez, Christina

AU - Stieber, Anne

AU - Hennigs, André

AU - Rauch, Geraldine

AU - Schuetz, Florian

AU - Sohn, Christof

AU - Schneeweiss, Andreas

AU - Golatta, Michael

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/12

Y1 - 2016/12

N2 - BACKGROUND: This study aimed to explore the ability of a minimal invasive biopsy to diagnose a pathological complete response (pCR = ypT0) in the breast.METHODS: Ultrasound-guided, vacuum-assisted, minimal invasive biopsy (VAB) was performed in 50 patients after neoadjuvant chemotherapy and before breast surgery. Negative predictive values (NPV) and false negative rates (FNR) to predict a pCR in surgical specimen were the main outcome measures. To assess the possible sampling error, the representativeness of the sample was evaluated by the biopsy performing physician (subjectively based on the visibility in ultrasound), by radiography of the biopsy specimen, and by the pathologist (based on histopathology).RESULTS: The cohort (n = 50) consisted of 15 (30%) triple negative breast cancers, 13 (26%) human epidermal growth factor receptor 2 (HER2) positive and 22 (44%) hormone receptor positive/HER2 negative cancers. ypT0 was diagnosed in 23 (46%) cases. In the overall cohort (n = 50), VAB yielded an NPV of 76.7% and an FNR of 25.9%. Given a representative VAB sample, according to the histopathological evaluation (n = 38), the NPV was 94.4% (95% CI 87.1-100.0) and the FNR 4.8% (95% CI 0.0-11.6). Non-representative VABs were mainly due to bad visibility of the target lesion in ultrasound.CONCLUSION: A VAB can accurately diagnose a pCR, given a histopathologically representative sample.

AB - BACKGROUND: This study aimed to explore the ability of a minimal invasive biopsy to diagnose a pathological complete response (pCR = ypT0) in the breast.METHODS: Ultrasound-guided, vacuum-assisted, minimal invasive biopsy (VAB) was performed in 50 patients after neoadjuvant chemotherapy and before breast surgery. Negative predictive values (NPV) and false negative rates (FNR) to predict a pCR in surgical specimen were the main outcome measures. To assess the possible sampling error, the representativeness of the sample was evaluated by the biopsy performing physician (subjectively based on the visibility in ultrasound), by radiography of the biopsy specimen, and by the pathologist (based on histopathology).RESULTS: The cohort (n = 50) consisted of 15 (30%) triple negative breast cancers, 13 (26%) human epidermal growth factor receptor 2 (HER2) positive and 22 (44%) hormone receptor positive/HER2 negative cancers. ypT0 was diagnosed in 23 (46%) cases. In the overall cohort (n = 50), VAB yielded an NPV of 76.7% and an FNR of 25.9%. Given a representative VAB sample, according to the histopathological evaluation (n = 38), the NPV was 94.4% (95% CI 87.1-100.0) and the FNR 4.8% (95% CI 0.0-11.6). Non-representative VABs were mainly due to bad visibility of the target lesion in ultrasound.CONCLUSION: A VAB can accurately diagnose a pCR, given a histopathologically representative sample.

U2 - 10.1016/j.ejca.2016.09.034

DO - 10.1016/j.ejca.2016.09.034

M3 - SCORING: Journal article

C2 - 27821317

VL - 69

SP - 142

EP - 150

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -